Anthera Pharma (ANTH) reported earnings on Wed 9 Aug 2017 (b/o)

** charts before earnings **

  

** charts after earnings **

Anthera Pharma reports Q2 results 

Anthera Pharma reports Q2 adjusted loss of ($0.86) ex-$0.83/share non operating gain of vs ($1.63) Capital IQ Consensus Estimate

• Co recorded non-cash, non-operating income of $9.0 million for the three and six months ended June 30, 2017, which reduced our per basic and diluted share from a loss of $0.86 to a net income of $0.03 for the three months ended June 30, 2017 and also reduced our per basic and diluted share from a loss of $2.35 to $1.58 for the six months ended June 30, 2017.
• Phase 3 RESULT study began screening patients in the U.S. and Europe
  • Topline data, which will be analyzed based on the 4-week primary treatment period, is expected at the end of 2017 or early 2018.